NCT03913130 - Extension Study to Study PQ-110-001 (NCT03140969) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 13, 2019

Primary Completion Date

October 3, 2022

Study Completion Date

October 3, 2022

Conditions

Leber Congenital Amaurosis 10BlindnessLeber Congenital AmaurosisVision DisordersSensation DisordersNeurologic ManifestationsEye DiseasesEye Diseases, HereditaryEye Disorders CongenitalRetinal Disease

Interventions

DRUG

QR-110

First treated eye: maintenance dose every 6 months, intravitreal administration Contralateral eye: loading dose followed by maintenance dose, every 6 months, intravitreal administration

Trial Locations (3)

19104

Scheie Eye Institute, University of Pennsylvania, Philadelphia

52242

University of Iowa, Iowa City

B-9000

Ghent University Hospital and Ghent University, Ghent